When biologics should be used in systemic lupus erythematosus

摘要: Recently, the use and evaluation of biologics increased in systemic lupus erythematosus (SLE). However, no international recommendation is available concerning with regards to subset patients who should be treated, optimal time treat, objective treatment manner discontinue it. To address these complex questions, we focused on already evaluated at least two published randomized controlled trials. We summarized results trials observational data registries. Taking into account clinical evidence, proposed some guidance way could used SLE. Many areas uncertainty persist require intensifying efforts from academic world set up new trials, develop recommendations.